Skip to content

Alamar Biosciences ALMR Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$1.1M-267%
GOL
Acushnet HoldingsGOLF
-$1.92M-192%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$887K+139%
Perimeter Solutions logo
Perimeter SolutionsPRM
$1.35M+16.6%
Bausch + Lomb logo
Bausch + LombBLCO
-$6M-200%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$8.22M-328%

Other financials

Income statement

See full
Revenue$26.0M+98.9%
Gross profit$14.5M+126%
Operating income-$12.3M-44.4%
Net income-$21.3M-178%
EPS (diluted)-$1.74-156%

Balance sheet

See full
Cash & equivalents$64.6M
Total debt$30.6M
Total equity-$178.1M
Total assets$186.5M

Cash flow

See full
Operating cash flow-$20.3M-55.7%
CapEx$600.0K+8.3%
Free cash flow-$20.9M-53.8%

Valuation

See full
Market cap$1.52B
Enterprise value$1.49B

Returns & leverage

See full
Debt / equity-0.2×
Current ratio5.9×

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's unrealized gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alamar Biosciences 's unrealized gain (loss), foreign currency transaction, before tax?
Alamar Biosciences (ALMR) reported unrealized gain (loss), foreign currency transaction, before tax of -$165K in Q1 2026.